Cardiovascular Diseases, Testicular Neoplasms
Conditions
Keywords
High-intensity interval training, VO2peak, Brachial flow-mediated dilation, Carotid-femoral pulse wave velocity, Carotid intima-media thickness, Carotid distensibility, Respiratory sinus arrhythmia
Brief summary
This study evaluates the impact of a supervised 12-week high-intensity aerobic interval exercise program (versus a self-directed exercise usual care group) on traditional and novel cardiovascular disease risk factors and surrogate markers of cardiovascular- and overall-mortality in a population-based sample of testicular cancer survivors.
Interventions
BEHAVIORALHigh-intensity aerobic interval exercise
See arm/group description
Sponsors
University of Alberta
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* histologically confirmed history of testicular cancer
Exclusion criteria
* Not sufficiently ambulatory to complete the first two stages of the aerobic exercise test. * Have a psychiatric condition which impairs their ability to perform the required volume and intensity of exercise. * Have any uncontrolled cardiovascular condition (i.e. heart disease, hypertension, diabetes, arrhythmia). * Report performing any weekly vigorous intensity aerobic exercise in the past month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak aerobic capacity (relative VO2peak) | Baseline and within 7 days of completing the 12-week intervention | ml O2/kg/min |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brachial diameter | Baseline and within 7 days of completing the 12-week intervention | mm |
| Total cholesterol : high-density lipoprotein ratio | Baseline and within 7 days of completing the 12-week intervention | ratio |
| Triglycerides | Baseline and within 7 days of completing the 12-week intervention | mmol/L |
| Fasting glucose | Baseline and within 7 days of completing the 12-week intervention | mmol/L |
| Testosterone | Baseline and within 7 days of completing the 12-week intervention | nmol/L |
| Framingham Risk Score | Baseline and within 7 days of completing the 12-week intervention | 10 year CVD risk % |
| Vascular age | Baseline and within 7 days of completing the 12-week intervention | years |
| Modifiable CVD Risk Factor Score | Baseline and within 7 days of completing the 12-week intervention | Number (max 24) |
| Peak aerobic capacity (absolute VO2peak) | Baseline and within 7 days of completing the 12-week intervention | L/min |
| Postexercise 1-minute heart rate recovery | Baseline and within 7 days of completing the 12-week intervention | change in beats/min |
| Heart rate | Baseline and within 7 days of completing the 12-week intervention | beats/min |
| Systolic blood pressure | Baseline and within 7 days of completing the 12-week intervention | mmHg |
| Diastolic blood pressure | Baseline and within 7 days of completing the 12-week intervention | mmHg |
| Respiratory sinus arrhythmia | Baseline and within 7 days of completing the 12-week intervention | beats/min |
| Average carotid intima-media thickness | Baseline and within 7 days of completing the 12-week intervention | mm |
| Maximal carotid intima-media thickness | Baseline and within 7 days of completing the 12-week intervention | mm |
| Carotid distensibility | Baseline and within 7 days of completing the 12-week intervention | 10-3/kPa |
| Carotid diameter | Baseline and within 7 days of completing the 12-week intervention | mm |
| Brachial flow-mediated dilation | Baseline and within 7 days of completing the 12-week intervention | percent dilation |
| Velocity time integral | Baseline and within 7 days of completing the 12-week intervention | cm |
| Shear stress during reactive hyperemia | Baseline and within 7 days of completing the 12-week intervention | dynes/cm2 |
| Carotid-femoral pulse wave velocity | Baseline and within 7 days of completing the 12-week intervention | m/s |
| Femoral-toe pulse wave velocity | Baseline and within 7 days of completing the 12-week intervention | m/s |
| Fibrinogen | Baseline and within 7 days of completing the 12-week intervention | g/L |
| High-sensitivity C-reactive protein | Baseline and within 7 days of completing the 12-week intervention | mg/L |
| Total cholesterol | Baseline and within 7 days of completing the 12-week intervention | mmol/L |
| High-density lipoprotein | Baseline and within 7 days of completing the 12-week intervention | mmol/L |
| Low-density lipoprotein | Baseline and within 7 days of completing the 12-week intervention | mmol/L |
Other
| Measure | Time frame | Description |
|---|---|---|
| Fatigue | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Functional Assessment of Cancer Therapy - Fatigue |
| Sleep Quality | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Global Pittsburg Sleep Quality Index |
| Anxiety | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Spielberger State Anxiety Scale |
| Stress | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Perceived Stress Scale |
| Self-Esteem | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Rosenberg Self-Esteem Scale |
| Depression | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Centre for epidemiologic studies depression scale |
| Health-related quality of life | Baseline, within 7 days of completing the 12-week intervention, and approximately 3 months after the post-intervention testing | Short form 36 |
Outcome results
None listed